Skip to content
Biodatica
Start free

Groupe Francophone des Myelodysplasies

Angers

OncologyPhase II
Compare Sign in to watch

What changed

Phase II trial registered: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

3mo agoTrial registeredMar 27, 2026Source filing (opens the source filing in a new tab)

Momentum

79no change

Momentum 79 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

739 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    NA registered

    Feb 26, 2024

    Acute Myeloid Leukemia · COMPLETED · sponsor: Centre Hospitalier Universitaire de Nice · Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven

    ClinicalTrials.gov · NCT06030089 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    May 3, 2023

    Acute Myeloid Leukemia · RECRUITING · sponsor: Centre Hospitalier Universitaire de Nice · CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

    ClinicalTrials.gov · NCT05260528 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Nov 23, 2022

    MDS, AML · ACTIVE_NOT_RECRUITING · sponsor: Groupe Francophone des Myelodysplasies · Venetoclax in Patients With MDS or AML in Relapse After AHSCT

    ClinicalTrials.gov · NCT05226455 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources